Navigation Links
ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients
Date:2/9/2009

- Conference Call at 10:00 A.M. Today to Discuss Results -

EXTON, Pa., Feb. 9 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that its Phase 3 trial evaluating maribavir used as prophylaxis in allogeneic stem cell, or bone marrow, transplant (SCT) patients did not achieve its primary endpoint. In the primary analysis, there was no statistically significant difference between maribavir and placebo in reducing the rate of CMV disease. In addition, the study failed to meet its key secondary endpoints. Maribavir was generally well tolerated in this clinical study.

"We are extremely disappointed by the outcome of this pivotal study," said Vincent J. Milano, ViroPharma's president and chief executive officer. "We just received these data and there are far more questions than answers; we still have a significant amount of work to do to fully understand this outcome and its impact on the overall program. Our disappointment is no doubt shared by physicians and transplant patients, who must today contend with CMV disease."

The primary endpoint of this Phase 3 study was the incidence of CMV disease, confirmed by an independent endpoint committee, within 6 months post-transplant. The incidence of CMV disease within 6 months was 4.4 percent for maribavir compared to 4.8 percent for placebo (P=0.79). The first of four key secondary endpoints was the rate of initiation of anti-CMV treatment within 6 months, which was 37.9 percent for maribavir compared to 40.5 percent for placebo (P=0.49). In addition, the incidence of graft-versus-host disease, mortality and CMV disease-free survival was comparable between the groups.

Conference Call and Webcast

ViroPharma is hosting a live teleconference and webcast with se
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. ViroPharma to Present at the 27th Annual J.P. Morgan Healthcare Conference
2. ViroPharma Provides Update on Vancocin(R)
3. ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema
4. ViroPharma To Present At The 20th Annual Piper Jaffray Healthcare Conference
5. ViroPharma to Discuss Commercialization and Launch of Cinryze(TM) on November 5, 2008
6. ViroPharma Incorporated Reports Third Quarter 2008 Financial Results
7. ViroPharma to Release 2008 Second Quarter Financial Results on July 30, 2008
8. ViroPharma Incorporated Reports First Quarter 2008 Financial Results
9. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results
10. Vincent J. Milano to Succeed Michel de Rosen as President and Chief Executive Officer of ViroPharma
11. ViroPharma Provides Update on Vancocin(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... December 25, 2014 Epigenetics finds applications ... research, including oncology, drug discovery, developmental biology, and research ... as one of the most widely used techniques for ... GLOBOCAN, the prevalence of cancer is rapidly growing worldwide. ... 8.2 million cancer deaths, and 32.6 million people living ...
(Date:12/24/2014)... 24, 2014 Dr. Vu Ho, a ... of his practice and med-spa with the addition of ... list of cosmetic treatments and services. , “Silk Peel ... skin,” says Dr. Ho. “As a result it can ... wrinkles, sun spots, discolorations or blemishes.” , Similar to ...
(Date:12/24/2014)... 24, 2014 Mike Billings , ... with Derek Fenwick, PT, MBA, GCS, Director of ... stem from the passing of the Improving Medicare ... In this taping of the Infinicast, the two leaders ... the Social Security Act to standardize post-acute assessment data ...
(Date:12/24/2014)... 24, 2014 (HealthDay News) -- A new, injectable weight-loss ... Drug Administration. The agency on Tuesday approved Saxenda ... who are overweight and have at least one weight-related ... diabetes or high cholesterol. Patients taking the drug, ... diet and exercise regularly, the FDA noted. "Obesity ...
(Date:12/24/2014)... Steven Reinberg HealthDay Reporter ... from the American Diabetes Association (ADA) call for giving the ... to help prevent heart disease. These new standards bring ... and American Heart Association, which also recommend giving low- or ... including people with diabetes. "We agree that the decision ...
Breaking Medicine News(10 mins):Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 3Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2Health News:Latest Episode of Infinicast Features Infinity Rehab President Discussing IMPACT Act of 2014 and Changes for Post-Acute Therapy Providers in 2015 2Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 2Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 3
... Aug. 13 As the debate over health care reform heats up, ... district has been, well, blunted. , , The billboard ... Blunt has taken $556,682 in contributions from the insurance industry. Is that ... , USAction and its Missouri affiliate, Missouri Progressive Vote Coalition, ...
... sexual assault and seeking help is difficult for anyone, but ... (LGBTQ) the thought of reporting a crime may well be ... a study in Oregon. The study, appearing in the ... found that 94 percent of respondents -- most of them ...
... , , , ... care industry moves from paper-based to electronic record-keeping, protecting confidential ... issue, Verizon is unveiling two new capabilities designed to help ... clinics, physicians, insurers and patients. , , ...
... , TORONTO, Aug. 13 /PRNewswire-FirstCall/ - Patheon Inc. (TSX: ... services to the global pharmaceutical industry, announced today that ... on Monday, September 14, 2009. , In conjunction with ... financial analysts on Monday, September 14, 2009 at 10:00 ...
... TOSU, SAGA, Japan, Aug. 13 Hisamitsu Pharmaceutical Co., Inc. ... announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust ... p.m., New York City time, on August 12, 2009, with respect ... NOVN ). , , ...
... Medical Research Council (MRC) scientists have made an important advance ... to die. The work may help scientists to eventually develop ... occur when cell death goes wrong. The research, published ... 14 August 2009) was carried out by a team of ...
Cached Medicine News:Health News:Blunted by Roy Blunt: The Billboard the Congressman Doesn't Want You to See 2Health News:Little safe haven for sexually assaulted LGBTQ victims 2Health News:Little safe haven for sexually assaulted LGBTQ victims 3Health News:Verizon Introduces New IT Security Capabilities for Health Care Industry 2Health News:Verizon Introduces New IT Security Capabilities for Health Care Industry 3Health News:Verizon Introduces New IT Security Capabilities for Health Care Industry 4Health News:Patheon Announces Date of Third Quarter 2009 Financial Results Release, Conference Call and Webcast 2Health News:Hisamitsu Pharmaceutical Announces Expiration of HSR Waiting Period for Its Proposed Acquisition of Noven Pharmaceuticals 2Health News:MRC scientists advance understanding of cell death 2
(Date:12/22/2014)... 22, 2014 NxStage Medical, Inc. (NASDAQ: ... dialysis products, announced today that the U.S. Food ... One™ to perform hemodialysis overnight while the patient ... hemodialysis. NxStage,s® System One is the first and ... this indication. Home nocturnal hemodialysis ...
(Date:12/22/2014)... 22, 2014   TRU-D SmartUVC LLC, producers ... robot, announced today that the General Services Administration has ... 2019.   This newly formed agreement will ... of government purchasers, including Department of Veteran Affairs and ... Security contacts purchasing solutions for the Ebola effort in ...
(Date:12/22/2014)... , Dec. 22, 2014 Cyberonics, Inc. (NASDAQ: ... the treatment and management of epilepsy, today announced it will ... Conference on Wednesday, January 14, 2015, in San ... President and Chief Executive Officer, will speak at 11:00 AM ... be accessed by clicking on the Investor Relations link on ...
Breaking Medicine Technology:NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3TRU-D SmartUVC LLC Awarded General Services Administration Contract to Expand Government Customer Base 2
... March 5, 2012 Medical Care Technologies Inc. ... Special Meeting of Shareholders of the Company,s common stock held ... for lack of quorum. The adjourned Special Meeting will occur ... to provide time for the shareholders to ensure that their ...
... Wash., March 5, 2012  SCOLR Pharma, Inc. (OTCQB: SCLR) ... product information and "where to buy" details for their ... available retailers can be found on www.scolr.com ... page can be reached from the home page or ...
Cached Medicine Technology:Medical Care Technologies Inc. Announces Adjournment of Special Meeting 2Medical Care Technologies Inc. Announces Adjournment of Special Meeting 3SCOLR Pharma, Inc. Provides Product Information on Website 2
... A fixed pipette is ideal ... single volume. Fixed volume FInnpipettes ... advantages as other Finnpipette Digital ... Super blow-out (1-40ul), Soft-touch tip ...
10L...
... and value!, Comfortable feel and ... contoured handle , Finer control while ... action , Completely autoclavable for easy ... for recalibration , Easy-to-read precision micrometer ...
... 2000 Pipette is a synonym for pipetting ... robust design, and superior operating comfort. Its ... the measuring stroke and blow-out as well ... system ensures utmost accuracy and precision. Ejection ...
Medicine Products: